Study opposes current drug treatment for asthma managementJanuary 27th, 2009 - 1:44 pm ICT by ANI
Washington, January 27 (ANI): A study from the University of Houston in the United States supports a controversial theory that opposes medicines that are presently in use for asthma management.
Research leader Richard A. Bond, professor of pharmacology, has revealed that present-day drugs work by stimulating a receptor found in many cells, including the smooth muscle lining the airways.
He says that while experimenting on mice, his team noticed that the animals that lacked a gene crucial for the production of this receptor did not show any symptoms of asthma.
That observation, adds Bond, was an indication that blocking the receptor, scientifically known as beta-2 adrenoreceptor, might be a safer and more effective strategy for long-term asthma management than stimulating it.
The researchers describe the strategy they have proposed as paradoxical pharmacology. It suggests that patients may be treated with medication that initially worsens their symptoms before eventually improving their overall health.
Bond concedes that beta blockers would not replace the need for emergency inhalers for acute episodes, but insists that the negative effects associated with beta blockers eventually taper off to provide long-term relief from asthma symptoms.
He also underscores a number of studies that have shown that chronic use of beta-2 stimulants can negatively affect asthma control and airway hyper-responsiveness.
During the current study, the researchers failed to trigger the development of asthma-like symptoms in a mouse model in which the beta-2 adrenoreceptor gene had been removed, compared to the mouse model with the intact receptor gene.
“The study indicates that, with regard to developing asthma-like features, the mouse is better off without the beta-2 adrenoreceptor at all,” Bond said.
“It means that whether we block receptor signalling pharmacologically by using beta blockers or genetically by ”removing” the receptor, we get the same answer. The research shows that blocking or inhibiting the receptor with antagonists, instead of stimulating it with agonists, reduces the asthma-like features of the mouse model,” he added.
The study has been published in the online edition of the journal Proceedings of the National Academy of Sciences (PNAS). (ANI)
- New therapeutic target for asthma, other lung disorders identified - Apr 18, 2011
- Culprit behind severe allergic asthma discovered - Aug 30, 2010
- Estrogen may reduce airway constriction in asthmatic women - May 17, 2010
- Drugs known to worsen asthma symptoms may indeed be beneficial - Apr 10, 2008
- Asthma drug could help fight Alzheimer's - Mar 27, 2011
- Anti-hypertensive drug improves multiple sclerosis-related brain inflammation - Jul 29, 2010
- Now, alternate therapy for adults with poorly controlled asthma - Sep 20, 2010
- Asthma drug could help fight Alzheimer's disease - Mar 26, 2011
- Liver, not brain, may be source of Alzheimer's plaques - Mar 04, 2011
- Soon, drugs that could treat cocaine addiction - Aug 11, 2010
- Asthma, pre-term labour drugs may increase autism risk in developing fetus - Dec 03, 2009
- Bitter tasting substances 'found to work better than drugs to treat asthma' - Oct 25, 2010
- Beta-blockers for heart patients a double-edged sword - Nov 22, 2009
- Internet monitoring strategy effective for severe asthma patients - May 17, 2010
- Delayed symptoms ravage asthmatics - Aug 14, 2011
Tags: acute episodes, asthma, asthma control, asthma management, asthma symptoms, beta 2 stimulants, beta blockers, bond professor, controversial theory, drugs work, inhalers, management research, mouse model, pharmacology, present day, receptor gene, research leader, responsiveness, smooth muscle, university of houston